我们很高兴地向大家介绍Medix Biochemica新任CEO：Steve Ferguson，他已于2020年1月1日就任。

在加入Medix Biochemica之前，Steve担任Thermo Fisher免疫诊断部门的欧洲商业运营副总裁；再之前，他在制药行业担任过各种管理职务。

在体外诊断行业的全球发展规划是Medix Biochemica的重中之重，对于Steve能够加入Medix的大家庭，并帮助Medix和Medix的合作伙伴携手并进，共续辉煌，我们感到无比高兴。

以下是Steve的访谈简报：

问题：请用自己的话描述一下您的目标是什么？

Question: In your own words, what do you do?

回答：我加入Medix是为了成就一个成功的企业，实现董事会的宏图，并让Medix Biochemica集团成为合作伙伴心目中的行业领导者。我希望实现公司愿景：成为IVD行业关键原料的首选供应商。作为首席执行官，我的职责是确保我们有明确的规划，并保证我们所有的员工、资产配置和投资活动都以实现这个愿景为共同目标。

Answer: I joined Medix to build on a successful business, to fulfill the ambition of the Board and to establish Medix Biochemica Group as the clear leader in the eyes of our customers. I want to deliver on our ambition to be the number one supplier of critical raw materials to the IVD industry. As CEO, my role is to ensure we have a clear plan in place, and all our people, assets and investments are aligned to deliver that ambition.

问题：您认为是什么让Medix Biochemica在行业中脱颖而出?

Question: What would you say makes Medix Biochemica stand out among other companies?

回答：高质量的产品，专业的员工，以及大规模生产的能力，无论是欧洲、美国还是中国，只要客户有需要。新的IVD法规意味着我们服务客户和加强供应链的愿望和行动完全符合IVD行业的需求。对我们的客户来说，IVD法规意味着更高的要求，且安全可靠的原料供应商极为重要。我们这方面的优势将有力地帮助合作伙伴完成适应新法规的转变。

Answer: The quality of our products, the expertise of our people, and our ability to scale manufacturing in the three regions where our customers need us: Europe, the US, and China. New regulations mean our desire to serve our customers and consolidate the supply chain is perfectly aligned to the needs of the IVD industry. IVD regulation is a burden to our customers and it means they must have secure and reliable raw material suppliers. We are in a great position to help our customers as they are going through change themselves.

问题：您认为Medix Biochemica的前景如何?

Question: How does Medix Biochemica’s future look like?

回答：前景灿烂，节奏明快！通过卓越的商业运营、加速的研发产品线和并购，我们将不断扩充提供给IVD合作伙伴的产品线，并成为最重要的供应商。2019年对Lee Biosolutions的收购，是我们扩充客户服务的第一步。这是众多审慎评估的并购计划中的第一个，我们将在2020年加快脚步。Medix集团正在不断发展，Medix大家庭也在不断壮大。对于每个Medix的成员来说，这将会是一个充满乐趣的旅程！

Question: Bright and fast-paced! Through commercial excellence, pipeline acceleration and inorganic acquisition, we will broaden our offering to IVD customers and become the most relevant supplier to them. The acquisition of Lee Bio Solutions in 2019 sees our first step in widening our customer offering. That is the first of many carefully planned acquisitions, and we will intensify our actions here in 2020. The Medix group is expanding and the Medix family is growing. This should be a fun journey for everyone at Medix!

如您有任何问题，请随时联系我们。 

Medix中国：

上海墨迪斯医疗技术有限公司

上海市浦东周浦天雄路588号21幢402室

电话：+86 21 6811 9180, 6811 9181, 6811 9105

传真：+86 21 6811 9125

邮箱：medixchina@medixbiochemica.com

中文网站：cnmedixbiochemica.com